{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:00:59Z","timestamp":1784977259930,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04258-z","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T14:59:12Z","timestamp":1771253952000},"page":"3206-3215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multigene panel testing reveals the spectrum of non-BRCA germline variants in BRCA1\/2-negative breast, ovarian, and prostate cancer patients from a Turkish cohort"],"prefix":"10.1007","volume":"28","author":[{"given":"Bar\u0131s","family":"Paksoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur","family":"Erkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0434-8445","authenticated-orcid":false,"given":"Ayca","family":"Kocaaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"4258_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15\u201323.","journal-title":"Breast"},{"issue":"1\u20132","key":"4258_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11864-009-0108-2","volume":"10","author":"T Sueblinvong","year":"2009","unstructured":"Sueblinvong T, Carney ME. Current understanding of risk factors for ovarian cancer. Curr Treat Options Oncol. 2009;10(1\u20132):67\u201381.","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"4258_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63\u201389.","journal-title":"World J Oncol"},{"issue":"6","key":"4258_CR4","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s12282-020-01148-2","volume":"28","author":"R Yoshida","year":"2021","unstructured":"Yoshida R. Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer. 2021;28(6):1167\u201380.","journal-title":"Breast Cancer"},{"issue":"4","key":"4258_CR5","doi-asserted-by":"publisher","first-page":"a016600","DOI":"10.1101\/cshperspect.a016600","volume":"7","author":"R Prakash","year":"2015","unstructured":"Prakash R, Zhang Y, Feng W, Jasin M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol. 2015;7(4):a016600.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"4258_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12957-024-03553-9","volume":"22","author":"M Pal","year":"2024","unstructured":"Pal M, Das D, Pandey M. Understanding genetic variations associated with familial breast cancer. World J Surg Oncol. 2024;22(1):271.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"4258_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41523-024-00686-8","volume":"10","author":"P Dubsky","year":"2024","unstructured":"Dubsky P, Jackisch C, Im SA, Hunt KK, Li CF, Unger S, et al. BRCA genetic testing and counseling in breast cancer: how do we meet our patients\u2019 needs? NPJ Breast Cancer. 2024;10(1):77.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"4258_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"19","author":"MB Daly","year":"2021","unstructured":"Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2021;19(1):77\u2013102.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"23","key":"4258_CR9","doi-asserted-by":"publisher","first-page":"12546","DOI":"10.3390\/ijms252312546","volume":"25","author":"P Nagy","year":"2024","unstructured":"Nagy P, Papp J, Grolmusz VK, Bozsik A, P\u00f3cza T, Ol\u00e1h E, et al. Comprehensive clinical genetics, molecular and pathological evaluation efficiently assist diagnostics and therapy selection in breast cancer patients with hereditary genetic background. Int J Mol Sci. 2024;25(23):12546.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"4258_CR10","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1200\/JCO.24.00662","volume":"42","author":"N Tung","year":"2024","unstructured":"Tung N, Ricker C, Messersmith H, Balma\u00f1a J, Domchek S, Stoffel EM, et al. Selection of germline genetic testing panels in patients with cancer: ASCO Guideline. J Clin Oncol. 2024;42(21):2599\u2013615.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4258_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/genes15020219","volume":"15","author":"V Barili","year":"2024","unstructured":"Barili V, Ambrosini E, Bortesi B, Minari R, De Sensi E, Cannizzaro IR, et al. Genetic basis of breast and ovarian cancer: approaches and lessons learnt from three decades of inherited predisposition testing. Genes (Basel). 2024;15(2):219.","journal-title":"Genes (Basel)"},{"issue":"2","key":"4258_CR12","doi-asserted-by":"publisher","first-page":"pkz028","DOI":"10.1093\/jncics\/pkz028","volume":"3","author":"S Yost","year":"2019","unstructured":"Yost S, Ruark E, Alexandrov LB, Rahman N. Insights into BRCA cancer predisposition from integrated germline and somatic analyses in 7632 cancers. JNCI Cancer Spectr. 2019;3(2):pkz028.","journal-title":"JNCI Cancer Spectr"},{"issue":"3","key":"4258_CR13","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3390\/ijms21031128","volume":"21","author":"D Angeli","year":"2020","unstructured":"Angeli D, Salvi S, Tedaldi G. Genetic predisposition to breast and ovarian cancers: how many and which genes to test? Int J Mol Sci. 2020;21(3):1128.","journal-title":"Int J Mol Sci."},{"issue":"1-2","key":"4258_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ahg.12488","volume":"87","author":"N Cine","year":"2023","unstructured":"Cine N, Ugurtas C, Gokbayrak M, Aydin D, Demir G, Kuru S, et al. The role of next-generation sequencing in the examination of signaling genes in Brca1\/2-negative breast cancer cases. Ann Hum Genet. 2023;87(1\u20132):28\u201349.","journal-title":"Ann Hum Genet"},{"issue":"1","key":"4258_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.29010","volume":"121","author":"N Tung","year":"2015","unstructured":"Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015;121(1):25\u201333.","journal-title":"Cancer"},{"issue":"8","key":"4258_CR16","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/gim.2014.176","volume":"17","author":"KN Maxwell","year":"2015","unstructured":"Maxwell KN, Wubbenhorst B, D\u2019Andrea K, Garman B, Long JM, Powers J, et al. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1\/2-negative patients with early-onset breast cancer. Genet Med. 2015;17(8):630\u20138.","journal-title":"Genet Med"},{"issue":"6","key":"4258_CR17","doi-asserted-by":"publisher","first-page":"e647","DOI":"10.1016\/j.clbc.2021.04.002","volume":"21","author":"A Ece Solmaz","year":"2021","unstructured":"Ece Solmaz A, Yeniay L, G\u00f6kmen E, Zekio\u011flu O, Haydaro\u011flu A, Bilgen I, et al. Clinical contribution of next-generation sequencing multigene panel testing for BRCA negative high-risk patients with breast cancer. Clin Breast Cancer. 2021;21(6):e647\u201353.","journal-title":"Clin Breast Cancer"},{"key":"4258_CR18","first-page":"1","volume":"15","author":"H Abdel-Razeq","year":"2023","unstructured":"Abdel-Razeq H, Abujamous L, Al-Azzam K, Abu-Fares H, Bani Hani H, Alkyam M, et al. Guideline-based, multi-gene panel germline genetic testing for at-risk patients with breast cancer. Breast Cancer (Dove Med Press). 2023;15:1\u201310.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"3","key":"4258_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.15386\/mpr-1083","volume":"92","author":"A Catana","year":"2019","unstructured":"Catana A, Apostu AP, Antemie RG. Multi gene panel testing for hereditary breast cancer\u2014is it ready to be used? Med Pharm Rep. 2019;92(3):220\u20135.","journal-title":"Med Pharm Rep"},{"issue":"1","key":"4258_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10549-018-4726-x","volume":"170","author":"J Singh","year":"2018","unstructured":"Singh J, Thota N, Singh S, Padhi S, Mohan P, Deshwal S, et al. Screening of over 1000 Indian patients with breast and\/or ovarian cancer with a multi-gene panel: prevalence of BRCA1\/2 and non-BRCA mutations. Breast Cancer Res Treat. 2018;170(1):189\u201396.","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"4258_CR21","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1111\/febs.13352","volume":"282","author":"F Aloraifi","year":"2015","unstructured":"Aloraifi F, McDevitt T, Martiniano R, McGreevy J, McLaughlin R, Egan CM, et al. Detection of novel germline mutations for breast cancer in non-BRCA1\/2 families. FEBS J. 2015;282(17):3424\u201337.","journal-title":"FEBS J"},{"issue":"2","key":"4258_CR22","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.3747\/co.25.3707","volume":"25","author":"KJ Jerzak","year":"2018","unstructured":"Jerzak KJ, Mancuso T, Eisen A. Ataxia-telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review. Curr Oncol. 2018;25(2):e176\u201380.","journal-title":"Curr Oncol"},{"issue":"13","key":"4258_CR23","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","volume":"34","author":"N Tung","year":"2016","unstructured":"Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34(13):1460\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4258_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-016-4038-y","volume":"161","author":"O Moran","year":"2017","unstructured":"Moran O, Nikitina D, Royer R, Poll A, Metcalfe K, Narod SA, et al. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel. Breast Cancer Res Treat. 2017;161(1):135\u201342.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"4258_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10689-016-9956-7","volume":"16","author":"S Yadav","year":"2017","unstructured":"Yadav S, Reeves A, Campian S, Paine A, Zakalik D. Outcomes of retesting BRCA negative patients using multigene panels. Fam Cancer. 2017;16(3):319\u201328.","journal-title":"Fam Cancer"},{"issue":"1, Supplement","key":"4258_CR26","doi-asserted-by":"publisher","first-page":"100058","DOI":"10.1016\/j.gimo.2023.100058","volume":"1","author":"D Stewart","year":"2023","unstructured":"Stewart D, Ramos M, Kim SY, Kim J, Haley J, Rao S, et al. O14: Risk of cancer from 6 common germline variants in CHEK2: a genome-first approach to the Geisinger and UK Biobank cohorts*. Genet Med Open. 2023;1(1, Supplement):100058.","journal-title":"Genet Med Open"},{"issue":"2","key":"4258_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10689-018-00114-4","volume":"18","author":"K Fulk","year":"2019","unstructured":"Fulk K, LaDuca H, Black MH, Qian D, Tian Y, Yussuf A, et al. Monoallelic MUTYH carrier status is not associated with increased breast cancer risk in a multigene panel cohort. Fam Cancer. 2019;18(2):197\u2013201.","journal-title":"Fam Cancer"},{"issue":"1","key":"4258_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.14744\/ejmo.2022.88057","volume":"6","author":"Y Sinem","year":"2022","unstructured":"Sinem Y, Serhat S, Fazli Cem G. Importance of diagnosis in breast cancer with non-BRCA pathogenic germline variants of cancer susceptibility genes using high-throughput sequencing analysis. Eurasian J Med Oncol. 2022;6(1):30\u201342.","journal-title":"Eurasian J Med Oncol"},{"issue":"3","key":"4258_CR29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/humu.24158","volume":"42","author":"PS Felicio","year":"2021","unstructured":"Felicio PS, Grasel RS, Campacci N, de Paula AE, Galv\u00e3o HCR, Torrezan GT, et al. Whole-exome sequencing of non-BRCA1\/BRCA2 mutation carrier cases at high-risk for hereditary breast\/ovarian cancer. Hum Mutat. 2021;42(3):290\u20139.","journal-title":"Hum Mutat"},{"issue":"10","key":"4258_CR30","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.30498","volume":"123","author":"SS Buys","year":"2017","unstructured":"Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017;123(10):1721\u201330.","journal-title":"Cancer"},{"issue":"11","key":"4258_CR31","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.3390\/cancers12113140","volume":"12","author":"M Zanti","year":"2020","unstructured":"Zanti M, Loizidou MA, Michailidou K, Pirpa P, Machattou C, Marcou Y, et al. NGS panel testing of triple-negative breast cancer patients in cyprus: a study of BRCA-negative cases. Cancers (Basel). 2020;12(11):3140.","journal-title":"Cancers (Basel)."},{"issue":"21","key":"4258_CR32","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.21037\/atm-20-2999","volume":"8","author":"GT Lang","year":"2020","unstructured":"Lang GT, Shi JX, Huang L, Cao AY, Zhang CH, Song CG, et al. Multiple cancer susceptible genes sequencing in BRCA-negative breast cancer with high hereditary risk. Ann Transl Med. 2020;8(21):1417.","journal-title":"Ann Transl Med"},{"key":"4258_CR33","doi-asserted-by":"publisher","first-page":"894358","DOI":"10.3389\/fmed.2022.894358","volume":"9","author":"M Nunziato","year":"2022","unstructured":"Nunziato M, Di Maggio F, Pensabene M, Esposito MV, Starnone F, De Angelis C, et al. Multi-gene panel testing increases germline predisposing mutations\u2019 detection in a cohort of breast\/ovarian cancer patients from Southern Italy. Front Med (Lausanne). 2022;9:894358.","journal-title":"Front Med (Lausanne)"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04258-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04258-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04258-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:29:17Z","timestamp":1784975357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04258-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4258"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04258-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The material and method (study population) section contains information about obtaining ethical consent. Informed consent was obtained from all patients.","order":2,"name":"Ethics","label":"Ethical approval (Research involving human participants and\/or animals) and Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A data availability statement may be considered if the corresponding author is contacted and ethical committee approval is obtained.","order":3,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}